Breaking Down Biogen: 8 Analysts Share Their Views
Portfolio Pulse from Benzinga Insights
Eight analysts have recently shared their views on Biogen (NASDAQ:BIIB), with opinions ranging from bullish to bearish. The average 12-month price target for BIIB has been adjusted to $291.0, down from $302.00, reflecting a 3.64% decline. Analyst actions include maintaining, raising, and lowering ratings and price targets, indicating varied perceptions of Biogen's market position. Biogen's financial performance shows strong net margin and ROE, but its revenue growth and market capitalization are below industry averages.
February 13, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Biogen's average 12-month price target has been adjusted to $291.0, reflecting analysts' mixed views and a 3.64% decline from the previous target. Despite strong profitability indicators, revenue growth and market capitalization are below industry averages.
The mixed analyst ratings and the adjustment in the average price target reflect uncertainty and varied expectations for Biogen's future performance. The strong net margin and ROE indicate good profitability, but the below-average revenue growth and market capitalization compared to industry peers could limit stock price appreciation in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100